阿托伐他汀对血脂正常的初诊2型糖尿病并发大血管病变患者超敏C反应蛋白的影响  

Influence of atorvastatin to high sensitive C-reactive protein in the new onset type 2 diabetes of normal blood lipid with macrovascular disease

作　　者：胡朝晖[1] 刘加和[1] 何冬娟[1] 万金星[1] 

机构地区：[1]衢州市人民医院内分泌科,浙江省衢州324000

出　　处：《中国基层医药》2009年第1期67-68,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的观察阿托伐他汀对血脂正常的初诊2型糖尿病大血管病变患者超敏C反应蛋白（hs-CRP）的影响。方法96例患者随机分为治疗组49例和对照组47例，两组患者均在饮食指导及生活方式干预基础上加用降糖治疗，治疗组加用阿托伐他汀10mg每晚1次，共12周。对照组予安慰剂12周。均空腹采血查两组空腹血糖（FBG）、餐后2h血糖（PPG）、糖化血红蛋白（HbA，c）、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白（LDL—C）、hs—CRP。结果治疗后治疗组hs—CRP水平显著低于对照组[（2．13±1．38）mg／L与（4．04±3．14）mg／L，P〈0．05]。结论阿托伐他汀能显著降低血脂正常的初诊2型糖尿病大血管病变患者hs—CRP水平，对预防动脉硬化的进展有良好作用。Objective To observe influence of atorvastatin to high sensitive C-reactive protein in the new onset type 2 diabetes of normal blood lipid with macrovascular disease. Methods 96 cases with the new onset type 2 diabetes of normal blood lipid with macrovascular disease were randomly divided into two groups, the treatment group contains 49 cases who were given atorvastatin 10mg for 12 weeks, the control group contains 47 cases who were given placebo for 12 weeks. Two groups were underwent the following test, fasting plasma glucose （FBG） , post-OGTT 2 hour plasma glucose （PPG） , glycosy-lated hemoglobin （ HbA1 c）, total triglyceride （ TG ）, total cholesterol （ TC ）, low density lipoprotein cholesterol（LDL-C） , high sensitive C-reactive protein （hs-CRP）. Results High sensitive C-reactive protein（hs-CRP） in treatment group is significantly lower than control group[ （2. 13 ± 1.38） mg/L and （4. 04 ± 3.14） mg/L,P 〈 0. 05 ]. Conclusion Atorvastatin can significantly decease the level of high sensitive C-reactive protein （hs-CRP） to the new onset type 2 diabetes of normal blood lipid with macrovascular disease.

关 键 词：糖尿病 2型 阿托伐他汀 C反应蛋白 大血管病变 

分 类 号：R587[医药卫生—内分泌]